Epithalon: Telomerase and Longevity Research Reviewed

Epithalon occupies an unusual position in the longevity literature. It is one of the most widely discussed peptides among people interested in aging, and one of the least studied by anyone outside the laboratory that created it. The compound is a four-residue peptide, alanine–glutamate–aspartate–glycine (AEDG), developed at the St Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson as a chemically defined stand-in for Epithalamin, a polypeptide extract of bovine pineal gland that Soviet gerontologists had studied since the 1970s. The claims made for it are large: reactivation of telomerase in normal human cells, extension of lifespan across species, suppression of certain tumors. This note reviews the primary sources behind each claim, describes the single independent replication that exists, and is candid about how much weight the record can bear. Wednesday does not list Epithalon; this is an educational review.

Origins: from pineal extract to tetrapeptide

Epithalamin was prepared from bovine pineal glands by acid extraction and was studied in rodents and, in small cohorts, in elderly patients in the Soviet Union and later Ukraine. In the 1990s Khavinson’s group set out to identify which short sequence within the extract accounted for its activity, and settled on AEDG. A 2017 paper from the same group reported detecting the AEDG sequence within the native pineal polypeptide complex by mass spectrometry, which is the main evidence that the synthetic peptide corresponds to something in the extract.⁸ The tetrapeptide was named Epithalon (Epitalon in some transliterations).

The pineal gland secretes melatonin, which declines with age, and the group’s early work framed both Epithalamin and Epithalon as agents that restore melatonin rhythm in aging animals. The telomerase hypothesis came later.

The telomerase claim

The most cited Epithalon paper is a two-page report in the Bulletin of Experimental Biology and Medicine from 2003. Khavinson, Bondarev and Butyugov cultured human fetal fibroblasts, which normally lack telomerase, and reported that adding Epithalon to the medium induced expression of the telomerase catalytic subunit, produced measurable telomerase activity, and lengthened telomeres.¹ A 2004 follow-up reported that treated fibroblast cultures continued dividing beyond the Hayflick limit reached by untreated cultures, while retaining a normal karyotype.²

These are striking results, and their limitations should be stated plainly. The reports are short, the methods sections are brief, sample sizes are not always given, and the telomerase assays used are described only in outline. The work was not replicated by any other laboratory for more than twenty years. A peptide of four amino acids reactivating telomerase in a normal somatic cell would be a remarkable finding, and remarkable findings from a single group in low-visibility journals warrant caution until confirmed.

A tetrapeptide that switches telomerase back on in ordinary human cells would be one of the more important discoveries in cell biology; for two decades, no one outside the originating laboratory checked.

The 2025 Brunel replication

In 2025 Al-dulaimi, Thomas, Matta and Roberts at Brunel University London published the first independent test of the telomerase claim in Biogerontology.⁷ They treated two normal human cell types, IBR.3 fibroblasts and HMEC mammary epithelial cells, with Epithalon for three weeks, and two breast-cancer lines, 21NT and BT474, for four days, at concentrations between 0.1 and 1.0 micrograms per milliliter.

In the normal cells, they found dose-dependent increases in hTERT expression and telomerase activity (a 4- to 26-fold rise) and significant telomere lengthening after three weeks, broadly consistent with the 2003 report. In the cancer lines the picture was different and less comfortable. hTERT mRNA rose 5- to 12-fold but telomerase activity did not increase significantly; instead telomeres lengthened markedly (from about 2.4 to 4 kilobases in 21NT and up to 8 kilobases in BT474) through the alternative lengthening of telomeres (ALT) pathway, with a tenfold increase in ALT activity in 21NT cells confirmed by C-circle assay. The authors noted that their qPCR method measures average telomere length across chromosomes, a limitation of the technique.⁷

Two conclusions follow. The telomerase effect in normal cells now has independent support, which is more than most claims in this area can say. And the peptide lengthened telomeres in cancer cells too, by a different route. Telomere maintenance is what allows tumor cells to divide indefinitely, so a compound that extends telomeres indiscriminately raises an obvious safety question that the Khavinson tumor studies, discussed next, do not settle.

Lifespan and tumor studies in animals

The Khavinson group published a series of lifespan experiments between 2000 and 2003. In Drosophila melanogaster, adding Epithalon to the larval medium at very low concentrations increased mean lifespan relative to untreated flies.³ In female Swiss-derived SHR mice (54 per group) given monthly Epithalon injections from age three months until death, Anisimov and colleagues reported slower age-related loss of estrous function, 17 percent fewer chromosome aberrations in bone-marrow cells, no change in mean lifespan, a 13 percent longer lifespan among the last 10 percent of survivors, and a 12 percent higher maximum lifespan. Total spontaneous tumor incidence was unchanged, but leukemia incidence was sixfold lower in treated animals.⁴ In HER-2/neu transgenic mice, which develop mammary carcinomas at high rates, Epithalon reduced tumor multiplicity and the size of the largest tumors, and lowered expression of the HER-2/neu transgene in tumor tissue, without changing tumor incidence.⁵

These studies were run at a well-regarded cancer institute in St Petersburg and are more detailed than the cell-culture reports. Their limitations are those of the era and setting: single-sex cohorts, no blinding described, and outcomes that vary across models (leukemia fell in SHR mice while total tumor incidence did not). The reduction in some tumor types sits awkwardly beside the 2025 finding that the peptide extends telomeres in cancer cells; the two observations may be reconciled by dose, timing or model, but the reconciliation has not been done.

Claim	Source	Model	Independent replication
Telomerase activation, telomere lengthening	Khavinson 2003, 20041,2	Human fetal fibroblasts	Yes, Brunel 2025, in normal cells; cancer cells also affected7
Lifespan extension	Khavinson 2000; Anisimov 20033,4	Fruit fly; female SHR mice	No
Fewer leukemias; smaller transgene-driven mammary tumors	Anisimov 2002, 20034,5	SHR and HER-2/neu mice	No
Slower aging in elderly patients	Korkushko 20116	Humans, Epithalamin extract, n=79	No; and not Epithalon

Human data: Epithalamin, not Epithalon

Claims that Epithalon extends human life trace to studies of the pineal extract, not the tetrapeptide. The most frequently cited is Korkushko and colleagues’ 2011 report of a 15-year follow-up of 79 patients with coronary heart disease in Kyiv, 39 of whom received courses of Epithalamin alongside standard therapy and 40 of whom received standard therapy alone. The authors reported slower decline in cardiovascular and physical-endurance measures, normalized melatonin rhythm and carbohydrate and lipid metabolism, and lower mortality in the treated group.⁶

The study was small, open-label, conducted by the developers of the compound, and reported in a four-page paper. No randomized, blinded trial of either Epithalamin or Epithalon has been published. Epithalon has no marketing authorization as a drug anywhere; in Russia, Epithalamin and related pineal peptide products have been sold as pharmaceuticals and later as supplements, but that regulatory history does not extend to the synthetic tetrapeptide in other jurisdictions.

Proposed mechanisms beyond telomerase

The Khavinson group has proposed that short peptides such as AEDG enter the nucleus and bind DNA directly at specific sequences, altering chromatin accessibility and gene expression. Supporting evidence consists of fluorescence-labeled peptide uptake in HeLa cells and in vitro binding to synthetic oligonucleotides, along with reported changes in expression of genes including telomerase, the circadian regulator CLOCK and melatonin-synthesis enzymes in cultured cells and animal tissue.^1,8 The Brunel authors observed hTERT upregulation consistent with a transcriptional effect but did not test a DNA-binding mechanism.⁷ Whether a four-residue acidic peptide can bind DNA with sequence specificity, survive intracellular proteases long enough to act, and do so at the nanomolar concentrations used is an open biophysical question.

What a careful reader should take away

Epithalon is a real compound with a real, if narrow, literature. The 2025 replication means the telomerase finding in normal fibroblasts can no longer be dismissed as an artifact of one laboratory, and that is a meaningful development. Everything else, including lifespan extension in animals, tumor suppression, and any effect in humans, rests on the original group’s work and has not been tested elsewhere. The finding that the peptide lengthens telomeres in cancer cells through ALT introduces a safety consideration that the field has not addressed.

For researchers, the useful questions are the unanswered ones: whether the telomerase effect reproduces in adult primary cells from multiple donors, whether it depends on cell type, what the peptide’s intracellular half-life is, and whether the tumor-suppressive and telomere-extending observations can both be true. For readers of the wider longevity literature, the compound is a case study in how a small body of unreplicated work can acquire a reputation out of proportion to its evidence. Related notes cover NAD+, mitochondrial-derived peptides and SS-31, where the evidence base is deeper. Our note on what “research use only” means explains how compounds like this are classified.

Frequently asked questions

What is Epithalon?

Epithalon, also written Epitalon, is the synthetic tetrapeptide Ala-Glu-Asp-Gly. It was developed by Vladimir Khavinson’s group in St Petersburg as a defined analog of Epithalamin, a polypeptide extract of bovine pineal gland. It is studied for effects on telomerase, lifespan and neuroendocrine regulation in cells and animals.

Does Epithalon activate telomerase?

In cultured human fibroblasts, yes, according to the original 2003 report and a 2025 independent replication from Brunel University London. The 2025 study also found that Epithalon lengthened telomeres in breast-cancer cell lines through the alternative lengthening pathway, which raises a safety question. No study has measured telomerase activity in people given the peptide.

Has Epithalon been shown to extend lifespan?

In fruit flies the Khavinson group reported longer mean lifespan, and in one strain of female mice a longer maximum lifespan without a change in mean lifespan. These studies have not been repeated by other laboratories. Human lifespan claims refer to small open-label studies of the pineal extract Epithalamin, not the synthetic peptide.

Is Epithalon approved anywhere?

No regulatory agency has approved Epithalon as a drug. Pineal peptide extracts have been sold in Russia under various classifications, but that history does not apply to the synthetic tetrapeptide elsewhere. It is available only as a research chemical.

Why is the Epithalon evidence considered weak?

Almost all of it comes from a single research group, appears in journals with limited external review, uses small samples and brief methods, and went unreplicated for over twenty years. The one independent study, in 2025, confirmed one cell-culture finding while adding a new concern. There are no controlled human trials.

References & further reading

1. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590–592. doi:10.1023/A:1025493705728 / PMID 12937682
2. Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004;137(5):503–506. PMID 15455129
3. Khavinson VKh, Izmaylov DM, Obukhova LK, Malinin VV. Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mech Ageing Dev. 2000;120(1–3):141–149. doi:10.1016/S0047-6374(00)00217-7 / PMID 11087911
4. Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193–202. doi:10.1023/A:1025114230714
5. Anisimov VN, Khavinson VKh, Provinciali M, et al. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer. 2002;101(1):7–10. doi:10.1002/ijc.10570
6. Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011;151(3):366–369. doi:10.1007/s10517-011-1332-x / PMID 22451889
7. Al-dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. doi:10.1007/s10522-025-10315-x
8. Khavinson VKh, Kopylov AT, Vaskovsky BV, Ryzhak GA, Lin’kova NS. Identification of peptide AEDG in the polypeptide complex of the pineal gland. Bull Exp Biol Med. 2017;164(1):41–43. doi:10.1007/s10517-017-3922-8